jcm-logo

Journal Browser

Journal Browser

Pharmacological Pain Management Advances

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Anesthesiology".

Deadline for manuscript submissions: 20 August 2026 | Viewed by 588

Special Issue Editor


E-Mail Website
Guest Editor
Private Institute of Neurological Sciences (IFNAP), Nuernberg, Germany
Interests: pain management; drug research; real-world evidence; health care research; neuropediatrics

Special Issue Information

Dear Colleagues,

We are pleased to announce a Special Issue of the Journal of Clinical Medicine titled “Pharmacological Pain Management Advances”. This Special Issue aims to bring together high-quality original research, comprehensive reviews, and clinical perspectives that contribute to a deeper understanding of current and emerging strategies in pain pharmacotherapy.

Effective pain management remains a central challenge in medicine, and the rapid development of novel pharmacological agents, targeted therapies, and personalized treatment concepts is reshaping clinical practice. With this Special Issue, we invite researchers, clinicians, and pharmaceutical experts to share new findings, discuss ongoing challenges, and highlight promising directions that can advance the field.

Topics of interest include, but are not limited to, the following:

  • Novel analgesic drug developments;
  • Mechanisms of action in pain pharmacology;
  • Opioid and non-opioid therapeutics;
  • Personalized and precision pain medicine;
  • Pharmacogenomics and biomarkers in pain treatment;
  • Drug interactions, efficacy, and safety considerations;
  • Innovative delivery systems for analgesics;
  • Evidence-based approaches to acute and chronic pain management;
  • Translational research and real-world evidence approaches bridging experimental findings and clinical practice.

Submission Information:

The Special Issue welcomes original research articles, reviews, systematic analyses, and clinical studies. All submissions will undergo rigorous peer review to ensure the highest scientific quality.

We warmly encourage you to contribute your latest findings and help shape a comprehensive scientific resource for clinicians and researchers worldwide. Your work will play a key role in advancing pharmacological pain management and improving patient outcomes.

We look forward to receiving your submission.

Dr. Michael A. Ueberall
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pain management
  • drug therapy
  • analgesics
  • co-analgesics
  • drug safety and drug interactions
  • real-world evidence

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 238 KB  
Article
PRIME-Teen—Treatment Persistence and Outcomes Associated with CGRP Monoclonal Antibodies Compared with Conventional Oral Preventives in Adolescents with High-Burden Migraine: An Exploratory Real-World Analysis from the German Pain e-Registry (GPeR)
by Michael A. Überall
J. Clin. Med. 2026, 15(5), 1976; https://doi.org/10.3390/jcm15051976 - 4 Mar 2026
Viewed by 372
Abstract
Background: Adolescent migraine is highly prevalent and associated with substantial functional and psychosocial burden. Conventional oral preventives are widely used off-label with limited pediatric efficacy and frequent tolerability problems. Real-world data on calcitonin gene-related peptide (CGRP) monoclonal antibodies in adolescents are scarce. [...] Read more.
Background: Adolescent migraine is highly prevalent and associated with substantial functional and psychosocial burden. Conventional oral preventives are widely used off-label with limited pediatric efficacy and frequent tolerability problems. Real-world data on calcitonin gene-related peptide (CGRP) monoclonal antibodies in adolescents are scarce. Methods: We conducted an exploratory, retrospective cohort analysis of depersonalized routine-care data from adolescents with migraine in the German Pain e-Registry. Patients were eligible if they had at least one 6-month episode with high-evidence conventional oral preventives (HECP) and one 6-month episode with a CGRP monoclonal antibody (CGRP-mAb), each with baseline and follow-up documentation, enabling intra-individual descriptive comparisons. The primary endpoint was a pragmatic composite of 6-month treatment persistence and ≥50% reduction in monthly migraine days (MMD). Secondary outcomes included MMD, MMD with acute medication (MMDAM), migraine-related sick-leave days (MMSLD), disability (MIDAS), and patient-reported psychosocial outcomes. Results: A total of 422 adolescents contributed 1448 HECP and 422 CGRP-mAb episodes. Premature discontinuation occurred in 68.8% (HECP) and 11.9% (CGRP-mAb) of episodes; corresponding 6-month persistence was 30.6% and 88.2%, respectively. Mean MMD decreased from 11.7 to 9.4 during HECP episodes and from 11.6 to 4.4 during CGRP-mAb episodes. A ≥50% MMD reduction occurred in 25.4% (HECP) and 70.9% (CGRP-mAb) of episodes; the composite endpoint was met in 23.7% and 69.9%, respectively. CGRP-mAb episodes were associated with numerically larger improvements across secondary outcomes. Conclusions: In this high-burden adolescent cohort, CGRP-mAb treatment episodes were associated with higher persistence and broader improvements than prior conventional preventive episodes. Given the retrospective, non-randomized, sequential design, these findings are hypothesis-generating and do not constitute evidence of comparative effectiveness. Controlled pediatric trials and long-term safety studies are warranted. Full article
(This article belongs to the Special Issue Pharmacological Pain Management Advances)
Back to TopTop